Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirill Peskov

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2020
Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With DurvalumabSergey Gavrilov, Kirill Zhudenkov, Gabriel Helmlinger, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 11, 2023
A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trialsVictoria Kulesh, Igor Vasyutin, Alina Volkova, et al.
Frontiers in Immunology|March 29, 2024
Mathematical modeling in autoimmune diseases: from theory to clinical applicationYaroslav Ugolkov, Antonina Nikitich, Cristina Leon, et al.
Diabetes, Obesity & Metabolism|April 18, 2018
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology modelVeronika Voronova, Kirill Zhudenkov, Robert C Penland, et al.
Frontiers in Immunology|February 14, 2025
Corrigendum: Mathematical modeling in autoimmune diseases: from theory to clinical applicationYaroslav Ugolkov, Antonina Nikitich, Cristina Leon, et al.
Computational and Structural Biotechnology Journal|October 17, 2024
Assessment of NSCLC disease burden: A survival model-based meta-analysis studyNataliya Kudryashova, Boris Shulgin, Nikolai Katuninks, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 22, 2022
A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnosticsKirill Zhudenkov, Sergey Gavrilov, Alina Sofronova, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 14, 2025
An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusAlina Volkova, Victor Sokolov, Florencia Tettamanti, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 25, 2021
Longitudinal FEV<sub>1</sub> and Exacerbation Risk in COPD: Quantifying the Association Using Joint ModellingKirill Zhudenkov, Robert Palmér, Alexandra Jauhiainen, et al.
Frontiers in Oncology|December 22, 2022
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistanceVeronika Voronova, Anastasia Vislobokova, Kerim Mutig, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2020
Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With DurvalumabSergey Gavrilov, Kirill Zhudenkov, Gabriel Helmlinger, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 11, 2023
A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trialsVictoria Kulesh, Igor Vasyutin, Alina Volkova, et al.
Frontiers in Immunology|March 29, 2024
Mathematical modeling in autoimmune diseases: from theory to clinical applicationYaroslav Ugolkov, Antonina Nikitich, Cristina Leon, et al.
Diabetes, Obesity & Metabolism|April 18, 2018
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology modelVeronika Voronova, Kirill Zhudenkov, Robert C Penland, et al.
Frontiers in Immunology|February 14, 2025
Corrigendum: Mathematical modeling in autoimmune diseases: from theory to clinical applicationYaroslav Ugolkov, Antonina Nikitich, Cristina Leon, et al.
Computational and Structural Biotechnology Journal|October 17, 2024
Assessment of NSCLC disease burden: A survival model-based meta-analysis studyNataliya Kudryashova, Boris Shulgin, Nikolai Katuninks, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 22, 2022
A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnosticsKirill Zhudenkov, Sergey Gavrilov, Alina Sofronova, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 14, 2025
An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus ErythematosusAlina Volkova, Victor Sokolov, Florencia Tettamanti, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 25, 2021
Longitudinal FEV<sub>1</sub> and Exacerbation Risk in COPD: Quantifying the Association Using Joint ModellingKirill Zhudenkov, Robert Palmér, Alexandra Jauhiainen, et al.
Frontiers in Oncology|December 22, 2022
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistanceVeronika Voronova, Anastasia Vislobokova, Kerim Mutig, et al.
Pageof 5